
Organon Acquires Commercialized Biosimilar to ACTEMRA from Biogen
Organon acquired regulatory and commercial rights in the United States for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion from Biogen. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 …